Privitera Is New 2nd Vice President of American Epilepsy Society
CINCINNATIMichael Privitera, MD, a professor in the University of Cincinnati (UC) Department of Neurology and Rehabilitation Medicine and director of the Epilepsy Center at the UC Neuroscience Institute (UCNI), has been appointed second vice president of the American Epilepsy Society.
Privitera previously served as treasurer of the society, which is the worlds largest association of professionals dedicated to the prevention, treatment and cure of epilepsy. The announcement was made at the societys 2013 annual meeting, being held in Washington, D.C.
Privitera has been a neurologist specializing in epilepsy and has headed the Epilepsy Center at UCNIone of four centers of excellence at UC Health and the UC College of Medicinefor more than 25 years. He has been a professor of neurology at UC for 14 of those years.
Privitera is an internationally recognized expert on advanced treatments for epilepsy and has dedicated his career to discovering new treatments and caring for people with epilepsy. He established the Epilepsy Center over 25 years ago as the first comprehensive epilepsy program in the region. He has published over 100 scientific articles and a book on epilepsy, and has directed over 50 clinical studies on epilepsy treatment.
Privitera received his undergraduate degree from Johns Hopkins University and his medical degree from the State University of New York-Upstate Medical Center. He completed his residency at Georgetown University and a fellowship at the University of Texas Southwestern Medical Center. He has received numerous awards and honors during his career.
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.